Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

FDA Grants Accelerated Approval to Melphalan Flufenamide for Relapsed or Refractory Multiple Myeloma

Evidence for efficacy is based on the results from the HORIZON study
20 Apr 2021
Anticancer agents & Biologic therapy;  Haematologic malignancies

On 26 February 2021, the US Food and Drug Administration (FDA) granted accelerated approval to melphalan flufenamide (PepaxtoOncopeptides AB) in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD-38 directed monoclonal antibody.

Efficacy was evaluated in HORIZON (NCT02963493), a multicentre, single-arm study. Eligible patients were required to have relapsed refractory multiple myeloma. Patients received melphalan flufenamide 40 mg intravenously on day 1 and dexamethasone 40 mg orally (20 mg for patients ≥75 years of age) on day 1, 8, 15 and 22 of each 28-day cycle until disease progression or unacceptable toxicity.

Efficacy was evaluated in a subpopulation of 97 patients who received four or more prior lines of therapy and were refractory to at least one proteasome inhibitor, one immunomodulatory agent, and a CD38-directed antibody. The main efficacy outcome measure was overall response rate (ORR) and duration of response (DoR) assessed by investigators according to the International Myeloma Working Group (IMWG) Criteria. The ORR was 23.7% (95% confidence interval [CI] 15.7, 33.4) and median DoR 4.2 months (95% CI: 3.2, 7.6).

Safety was evaluated in the 157 patients enrolled in HORIZON. Most common adverse reactions (>20%) are fatigue, nausea, diarrhoea, pyrexia and respiratory tract infection. Most common laboratory abnormalities (≥50%) are decreased leukocytes, platelets, lymphocytes, neutrophils, and haemoglobin, and increased creatinine.

The safety and efficacy of melphalan flufenamide has not been established for use as a conditioning regimen in patients receiving transplant. The USPI includes Limitations of Use statement that melphalan flufenamide is not indicated and is not recommended for use as a conditioning regimen for transplant outside of controlled clinical trials.

The recommended dose of melphalan flufenamide is 40 mg intravenously over 30 minutes on day 1 of each 28-day treatment cycle, in combination with dexamethasone.

Full prescribing information for Pepaxto is available here.

This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

This application was granted priority review and orphan drug designation.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System.

For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact FDA’s Oncology Center of Excellence Project Facilitate.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings